p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1 -mediated down-regulation of CXCL12
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1 -mediated down-regulation of CXCL12
Authors
Keywords
-
Journal
BLOOD
Volume 118, Issue 16, Pages 4431-4439
Publisher
American Society of Hematology
Online
2011-08-26
DOI
10.1182/blood-2011-02-334136
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo
- (2011) T. Sato et al. BLOOD
- SOCS3 regulates graft-versus-host disease
- (2010) G. R. Hill et al. BLOOD
- FLT3 as a therapeutic target in AML: still challenging after all these years
- (2010) T. Kindler et al. BLOOD
- Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia
- (2010) J. Long et al. BLOOD
- Autocrine Induction of Invasive and Metastatic Phenotypes by the MIF-CXCR4 Axis in Drug-Resistant Human Colon Cancer Cells
- (2010) Anne-Frédérique Dessein et al. CANCER RESEARCH
- Phase I study of sorafenib in patients with refractory or relapsed acute leukemias
- (2010) G. Borthakur et al. HAEMATOLOGICA
- CXC Chemokine Receptor 4 Is a Cell Surface Receptor for Extracellular Ubiquitin
- (2010) Vikas Saini et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia
- (2010) Farhad Ravandi et al. JOURNAL OF CLINICAL ONCOLOGY
- Drug resistance in mutant FLT3-positive AML
- (2010) E Weisberg et al. ONCOGENE
- FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation
- (2009) G. Yoshimoto et al. BLOOD
- Survivin mediates aberrant hematopoietic progenitor cell proliferation and acute leukemia in mice induced by internal tandem duplication of Flt3
- (2009) S. Fukuda et al. BLOOD
- AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
- (2009) P. P. Zarrinkar et al. BLOOD
- KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation
- (2009) Y. Shiotsu et al. BLOOD
- Nutlin-3, an Hdm2 antagonist, inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated inactivation of HIF-1α
- (2009) Yoon-Mi Lee et al. CARCINOGENESIS
- Doxorubicin: The Good, the Bad and the Ugly Effect
- (2009) Cristina Carvalho et al. CURRENT MEDICINAL CHEMISTRY
- A functional heteromeric MIF receptor formed by CD74 and CXCR4
- (2009) Verena Schwartz et al. FEBS LETTERS
- Dissection of PIM serine/threonine kinases in FLT3-ITD–induced leukemogenesis reveals PIM1 as regulator of CXCL12–CXCR4-mediated homing and migration
- (2009) Rebekka Grundler et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 through Mcl-1/Noxa axis
- (2009) K Kojima et al. LEUKEMIA
- AMD3100 Is a CXCR7 Ligand with Allosteric Agonist Properties
- (2009) I. Kalatskaya et al. MOLECULAR PHARMACOLOGY
- New agents in acute myeloid leukemia: Beyond cytarabine and anthracyclines
- (2009) Amir T. Fathi et al. Current Oncology Reports
- CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure
- (2008) M. Fiegl et al. BLOOD
- A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response
- (2008) K. W. Pratz et al. BLOOD
- Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML
- (2008) Z. Zeng et al. BLOOD
- Unique Biology of Mcl-1: Therapeutic Opportunities in Cancer
- (2008) Gordon Shore et al. CURRENT MOLECULAR MEDICINE
- Mutant FLT3: A Direct Target of Sorafenib in Acute Myelogenous Leukemia
- (2008) Weiguo Zhang et al. JNCI-Journal of the National Cancer Institute
- Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition
- (2008) S. Shangary et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started